Basilea Buoyant As Antibiotic Finally Gets US Nod

Sales of the Swiss firm’s Zevtera are set to rocket after the beta-lactam antibiotic got approval from the US Food and Drug Administration. Now Basilea needs to sign up a commercial partner.

David Veitch
CEO David Veitch • Source: Basilea

Basilea Pharmaceutica Ltd. has secured a transformational approval across the Atlantic for Zevtera nearly 15 years after the US Food and Drug Administration rejected the Swiss biotech's antibiotic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas